DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Yuen MF, Agarwal K, Gane EJ. et al.
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Lancet Gastroenterol Hepatol 2020;
5 (02) 152-166
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.